Clinical Trial Update: Study Evaluating Safety And Tolerability Of Meningococcal B Rlp2086 Vaccine In Healthy Adults [Phase 1]

View source ↗

Summary

Pfizer conducted a Phase 1 trial to evaluate the safety and tolerability of the meningococcal B vaccine RLP2086 in healthy adults; results were posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meningococcal Meningitis

Drugs mentioned

• rLP2086 vaccine

Snippet

Sponsor: Pfizer | Conditions: Meningitis, Meningococcal | Phase 1 | Status: COMPLETED | Results posted: 2014-11-25